CC
ZSAN

Callan Capital’s Zosano Pharma Corporation ZSAN Stock Holding History

Callan Capital’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24
Closed -$13K – 46
2016
Q3 		$13K Buy
+24
New +$19.1K 0.01% 44

Other funds holding ZSAN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GA
Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Callan Capital's ZSAN Position: Q4 2016 in Review

Callan Capital sold out of Zosano Pharma Corporation (ZSAN) in Q4 2016, closing a stake of 24 shares — an estimated $13K sold.

Callan Capital first reported a position in ZSAN in Q3 2016 and held it in 1 quarter. The position peaked at $13K in Q3 2016. 15 funds tracked by Wall St. Rank hold ZSAN as of Q4 2016.

  • Callan Capital reported no remaining Zosano Pharma Corporation position as of Q4 2016 after selling out during the quarter.
  • Callan Capital sold 24 Zosano Pharma Corporation shares in Q4 2016, an estimated $13K.
  • Callan Capital first reported a position in Zosano Pharma Corporation in Q3 2016 and held it in 1 quarter.
  • Callan Capital's Zosano Pharma Corporation position peaked at $13K in Q3 2016.
  • 15 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q4 2016.

Based on Callan Capital's 13F filing for Q4 2016, filed 9 Feb 2017.